Unknown PHASE2 INTERVENTIONAL 1-arm NCT04269525

Umbilical Cord(UC)-Derived Mesenchymal Stem Cells(MSCs) Treatment for the 2019-novel Coronavirus(nCOV) Pneumonia

Clinical Research Regarding the Availability and Safety of UC-MSCs Treatment for Serious Pneumonia and Critical Pneumonia Caused by the 2019-nCOV Infection

Sponsor: Tuohua Biological Technology Co. Ltd

Conditions Pneumonia, Ventilator-Associated Pneumonia, Viral

Interventions UC-MSCs

Updated 7 times since 2020 Last updated: Jun 29, 2020 Started: Feb 6, 2020 Primary completion: Dec 1, 2020 Completion: Dec 30, 2020

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Pneumonia, Ventilator-Associated and Pneumonia, Viral and is currently ongoing. Tuohua Biological Technology Co. Ltd leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jul 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status
Jan 2021 — Jul 2022 [monthly]

Recruiting PHASE2
Aug 2020 — Jan 2021 [monthly]

Recruiting PHASE2

▶ Show 2 earlier versions

Jul 2020 — Aug 2020 [monthly]

Recruiting PHASE2
Mar 2020 — Jul 2020 [monthly]

Recruiting PHASE2

First recorded

Feb 2020

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tuohua Biological Technology Co. Ltd
ZhiYong Peng

Data source: Zhongnan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Wuhan, China